.sub-header{display:none;}
Lev Gerlovin, Ezra Josephson | Life Sciences
–>
Lev Gerlovin explores the future of payer response to rising drug prices and discuss strategies that manufacturers may consider to gain a competitive edge in this evolving landscape.
Pricing implications for drugs included in China’s Rare Diseases Catalogue (RDC)
China’s Rare Disease Catalogue (RDC) plays a growing role in shaping awareness, investment, and access to therapies for rare diseases in China.